...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Reversible Nephrotoxic Reactions to a Combined 2,3-Dimercapto-1-propanol and Calcium Disodium Ethylenediaminetetraacetic Acid Regimen in Asymptomatic Children with Elevated Blood Lead Levels
【24h】

Reversible Nephrotoxic Reactions to a Combined 2,3-Dimercapto-1-propanol and Calcium Disodium Ethylenediaminetetraacetic Acid Regimen in Asymptomatic Children with Elevated Blood Lead Levels

机译:血铅水平升高的无症状儿童对2,3-二巯基-1-丙醇和乙二胺四乙酸钙二钠联合治疗的可逆肾毒性反应

获取原文

摘要

One hundred thirty children aged 1 to 8 years with blood lead levels 50 μg/100 ml of whole blood (WB) and free erythrocyte protoporphyrin (FEP) concentration 250 μg/100 ml of WB received 207 chelation treatments for plumbism. All chelation treatments consisted of CaNa2 ethytenediaminetetraacetic acid (EDTA) 25 mg/kg per dose every 12 hours and 2,3-dimercapto-1-propanol (BAL) 3 mg/kg per dose every four hours for five days. Seventeen children demonstrated a transient doubling of pre-chelation treatment serum creatinine (≤ 2.0 mg/100 ml) during or following chelation treatment; 5/17 also had mild proteinuria. Four children developed severe oliguric ( 250 ml/sq m/day) acute renal failure. Serum creatinine levels were elevated six to seven days after chelation treatment was started and reached maximal values of 3.9 to 8.4 mg/100 ml, three to six days later. Renal function returned to pre-chelation treatment values during the subsequent six to 18 days. In the 21 nephrotoxic patients and the 109 nontoxic patients there were no significant differences in age (3.8 ± 0.6 vs 3.2 ± 0.2 years), sex (61% vs 53% males), percent who received multiple chelation treatments (38% vs 30%), blood lead levels (85 ± 5 vs 79 ± 1 μg/100 ml of WB), FEP (380 ± 30 vs 382 ± 18 μg/100 ml of WB), hemoglobin (11.5 ± 0.4 vs 11.1 ± 0.2 gm/100 ml, and pre-chelation treatment serum creatinine (0.46 ± 0.06 vs 0.58 ± 0.03 mg/100 ml). It was concluded that 13% of children with plumbism who received chelation treatments developed mild transient biochemical evidence of nephrotoxicity and another 3% developed acute renal failure characterized by oliguria four to eight days after chelation treatment was discontinued.
机译:一百三十名年龄在1至8岁的儿童的血铅水平> 50μg/ 100 ml全血(WB),并且游离红细胞原卟啉(FEP)浓度> 250μg/ 100 ml WB,接受了207种螯合治疗。所有螯合处理均由每12小时每剂25毫克/千克的CaNa2乙二胺四乙酸(EDTA)和每四小时每剂3毫克/千克的2,3-二巯基-1-丙醇(BAL)组成,持续5天。在螯合治疗期间或之后,有十七名儿童表现出螯合治疗前血清肌酐(≤2.0 mg / 100 ml)的短暂加倍; 5/17也有轻度蛋白尿。四名儿童出现严重的少尿(> 250 ml / sq m /天)急性肾衰竭。螯合治疗开始后六至七天,血清肌酐水平升高,三至六天后,血清肌酐水平达到最大值3.9至8.4 mg / 100 ml。在随后的六到十八天内,肾功能恢复到螯合前的治疗值。在21名肾毒性患者和109名非毒性患者中,年龄(3.8±0.6 vs 3.2±0.2岁),性别(61%vs 53%男性),接受多次螯合治疗的百分比(38%vs 30%)无显着差异。 ),血铅水平(85±5 vs 79±1μg/ 100 ml WB),FEP(380±30 vs 382±18μg/ 100 ml WB),血红蛋白(11.5±0.4 vs 11.1±0.2 gm / 100毫升和螯合前治疗后的血清肌酐(0.46±0.06 vs 0.58±0.03 mg / 100 ml)得出结论,接受螯合治疗的铅中毒患儿中有13%出现了短暂的肾毒性短暂生化证据,另有3%出现了急性肾毒性螯合治疗后四到八天,以少尿为特征的肾衰竭被终止。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号